DAVID PENA: Open Payments
NPI 1972807345 · CLOVIS, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,894 in 132 payments from 23 companies in 2025. Trend: 2023 $4,681 · 2024 $5,219 · 2025 $4,894
Food & beverage: $4,894
| Company | Payments | Amount |
|---|---|---|
| Corcept Therapeutics | 15 | $786 |
| Novo Nordisk Inc | 23 | $573 |
| Lilly USA, LLC | 12 | $474 |
| ABBVIE INC. | 12 | $472 |
| Xeris Pharmaceuticals, Inc. | 17 | $398 |
| Amgen Inc. | 11 | $379 |
| Ardelyx, Inc. | 6 | $280 |
| AstraZeneca Pharmaceuticals LP | 7 | $251 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $247 |
| RECORDATI_RARE_DISEASES_INC. | 6 | $206 |
Products named: Korlym, RECORLEV, Ozempic, VRAYLAR, IBSRELA, CAPLYTA, JARDIANCE, MOUNJARO.
Industry payments across CA — which companies pay providers there.
